JP2014139255A5 - - Google Patents

Download PDF

Info

Publication number
JP2014139255A5
JP2014139255A5 JP2014097072A JP2014097072A JP2014139255A5 JP 2014139255 A5 JP2014139255 A5 JP 2014139255A5 JP 2014097072 A JP2014097072 A JP 2014097072A JP 2014097072 A JP2014097072 A JP 2014097072A JP 2014139255 A5 JP2014139255 A5 JP 2014139255A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
tissue
nitrite
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014097072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014139255A (ja
JP5908527B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014139255A publication Critical patent/JP2014139255A/ja
Publication of JP2014139255A5 publication Critical patent/JP2014139255A5/ja
Application granted granted Critical
Publication of JP5908527B2 publication Critical patent/JP5908527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014097072A 2007-11-15 2014-05-08 慢性虚血における亜硝酸塩の使用 Expired - Fee Related JP5908527B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US315007P 2007-11-15 2007-11-15
US61/003,150 2007-11-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010534267A Division JP5795165B2 (ja) 2007-11-15 2008-11-17 慢性虚血における亜硝酸塩の使用

Publications (3)

Publication Number Publication Date
JP2014139255A JP2014139255A (ja) 2014-07-31
JP2014139255A5 true JP2014139255A5 (cg-RX-API-DMAC10.html) 2014-09-11
JP5908527B2 JP5908527B2 (ja) 2016-04-26

Family

ID=40639493

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534267A Expired - Fee Related JP5795165B2 (ja) 2007-11-15 2008-11-17 慢性虚血における亜硝酸塩の使用
JP2014097072A Expired - Fee Related JP5908527B2 (ja) 2007-11-15 2014-05-08 慢性虚血における亜硝酸塩の使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010534267A Expired - Fee Related JP5795165B2 (ja) 2007-11-15 2008-11-17 慢性虚血における亜硝酸塩の使用

Country Status (7)

Country Link
US (2) US9649334B2 (cg-RX-API-DMAC10.html)
EP (1) EP2219657A4 (cg-RX-API-DMAC10.html)
JP (2) JP5795165B2 (cg-RX-API-DMAC10.html)
CN (1) CN101939014B (cg-RX-API-DMAC10.html)
AU (1) AU2008322437B2 (cg-RX-API-DMAC10.html)
IL (1) IL205720A (cg-RX-API-DMAC10.html)
WO (1) WO2009065142A2 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065142A2 (en) 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
WO2010147742A2 (en) * 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
CN107260756A (zh) 2009-10-14 2017-10-20 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用
US20130209584A1 (en) * 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
CN105358160A (zh) 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
WO2017132275A1 (en) 2016-01-27 2017-08-03 Syk Technologies, Llc Nitric oxide topical application apparatus and methods
KR20200083974A (ko) * 2017-09-05 2020-07-09 엑셀 메드, 엘엘씨 허혈 치료용 헤파린 조성물
WO2020141546A1 (en) 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
US12459820B2 (en) 2020-06-11 2025-11-04 J. W. Randolph Miller Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
WO2000003725A1 (en) 1998-07-14 2000-01-27 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
JP2002535353A (ja) 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク 医薬品組成物
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
JP2004505056A (ja) * 2000-07-28 2004-02-19 バイオエナジー　インコーポレイティド 心血管の機能を向上する為の組成物及び方法
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
EP1492509A1 (en) 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
WO2005004884A2 (en) 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
JP2007502831A (ja) 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
CA2608651A1 (en) 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
CA2641950A1 (en) 2006-02-10 2007-08-23 Mannatech, Inc. All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
WO2007149520A2 (en) * 2006-06-21 2007-12-27 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
CA2678093C (en) 2007-02-26 2017-10-24 Jon Lundberg Performance enhancing composition and use thereof
KR20100014853A (ko) 2007-02-26 2010-02-11 존 런드버그 아질산염 및 질산염의 신규 용도 및 이를 함유하는 조성물
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
WO2009065142A2 (en) 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
US20090196930A1 (en) 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
WO2010147742A2 (en) 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
CN107260756A (zh) * 2009-10-14 2017-10-20 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
WO2012135623A1 (en) 2011-03-31 2012-10-04 Theravasc Inc. Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US20140112983A1 (en) 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications
CN105358160A (zh) * 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途

Similar Documents

Publication Publication Date Title
JP2011503212A5 (cg-RX-API-DMAC10.html)
JP2020033360A5 (cg-RX-API-DMAC10.html)
JP2020534270A5 (cg-RX-API-DMAC10.html)
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
JP2021504423A5 (cg-RX-API-DMAC10.html)
FI3716979T3 (fi) 4-pyrimidiinisulfamidijohdannaisen ja SGLT-2-inhibiittorin yhdistelmä endoteliiniin liittyvien sairauksien hoitamiseksi
JP2015526458A5 (cg-RX-API-DMAC10.html)
JP2019517542A5 (cg-RX-API-DMAC10.html)
JP2020508339A5 (cg-RX-API-DMAC10.html)
JP2014077003A5 (cg-RX-API-DMAC10.html)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2010522242A5 (cg-RX-API-DMAC10.html)
RU2020107416A (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
JP2011518787A5 (cg-RX-API-DMAC10.html)
JP2015522603A5 (cg-RX-API-DMAC10.html)
RU2014112324A (ru) Применение органического соединения для лечения синдрома нунан
JP2023531930A5 (cg-RX-API-DMAC10.html)
EA201792565A1 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
JP2019529569A5 (cg-RX-API-DMAC10.html)
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
JP4839309B2 (ja) 血栓症治療剤
RU2018119085A (ru) Схема введения ингибитора фосфатидилинозитол-3-киназы
RU2019110264A (ru) Циклическое соединение